Vimta Labs Limited has informed the Exchange about Investor Presentation
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vimta Labs, a 41-year-old contract research and testing (CRTO) company, posted Q2 FY26 total income of Rs 1,045 Mn (up 22.3% YoY) and H1 FY26 income of Rs 2,038 Mn (up 26.6% YoY). H1 FY26 EBITDA grew 26.4% YoY to Rs 723 Mn with margins holding steady at 35.5%, while PAT rose 25.5% YoY to Rs 388 Mn (19% margin). The company invested Rs 478 Mn in capex during H1 FY26 and ended the period with Rs 545 Mn in cash versus just Rs 68 Mn in debt, leaving it net cash positive. It claims the #1 position in India in Pharma Analytical and Food Testing, and highlighted growth runway in pharma, food, electronics and environment testing markets.
Strong double-digit revenue and profit growth, stable margins around 35% EBITDA / 19% PAT, and a net-cash balance sheet are positives for shareholders. The high capex outflow in H1 may pressure near-term free cash flows, but supports future growth capacity.